PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Genet Med. Author manuscript; available in PMC Sep 12, 2011.
Published in final edited form as:
PMCID: PMC3170997
NIHMSID: NIHMS320446
Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk
Kurt D. Christensen, MPH,1 J. Scott Roberts, PhD,1 Wendy R. Uhlmann, MS,2 and Robert C. Green, MD, MPH3
1Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, Michigan
2Departments of Internal Medicine and Human Genetics, University of Michigan, Ann Arbor, Michigan
3Departments of Neurology, Medicine (Genetics Program), and Epidemiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts
Kurt D. Christensen, MPH, Department of Health Behavior and Health Education, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109-2029. kdchrist/at/umich.edu
Purpose
Perceptions about the pros and cons of genetic susceptibility testing are among the best predictors of test utilization. How actual testing changes such perceptions has yet to be examined.
Methods
In a clinical trial, first-degree relatives of patients with Alzheimer disease received genetic risk assessments for Alzheimer disease including APOE disclosure. Participants rated 11 possible benefits associated with genetic testing (pros) and 10 risks or limitations (cons) before genetic risk disclosure and again 12 months afterward.
Results
Pros were rated higher than cons at baseline (3.53 vs. 1.83, P < 0.001) and at 12 months after risk disclosure (3.33 vs. 1.88, P < 0.001). Ratings of pros decreased during the 12-month period (3.33 vs. 3.53, P < 0.001). Ratings of cons did not change (1.88 vs. 1.83, P = 0.199) except for a three-item discrimination subscale which increased (2.07 vs. 1.92, P = 0.012). Among specific pros and cons, three items related to prevention and treatment changed the most.
Conclusion
The process of APOE genetic risk assessment for Alzheimer disease sensitizes some to its limitations and the risks of discrimination; however, 1-year after disclosure, test recipients still consider the pros to strongly outweigh the cons.
Keywords: Alzheimer, pros, cons, benefits, discrimination, genetics, risk, APOE, susceptibility testing, education
The rapid emergence of genetic susceptibility tests for common diseases highlights a need to understand how users appraise them. Perceptions about the benefits and advantages (pros) and the risks and limitations (cons) of genetic susceptibility tests are among the most powerful predictors of test utilization14 and are central constructs in many popular theories of health behavior and decision making such as the Health Belief Model5 and the Theory of Planned Behavior.6 Many studies have examined the association between perceived pros and cons and factors such as race,79 age,9 gender,10 education,9 personal history of disease,11 perceived risk of disease,11 and medical mistrust.12 An important factor that has been neglected in research on such perceptions is the experience of genetic testing itself.
Examining how perceptions of the pros and cons change after actual genetic susceptibility testing should provide insight about how well initial expectations match the real experience. Reasons exist to believe they might not. Misconceptions about genetics and genetic services among the public are widespread.1317 Television shows and movies frequently exaggerate the capabilities of genetic services or focus on highly deterministic forensic uses,18 and the media often exaggerate the benefits of genetic research while underrepresenting its risks and limitations.19,20 In addition, marketing for consumer genetic services can be confusing or misleading.21,22 On the other hand, individuals who seek genetic susceptibility tests tend to be highly educated,23,24 satisfaction with decisions about genetic testing is usually high,25,26 and evidence to date suggests that many individuals follow through on testing recognizing that it has limitations and risks.27 Individuals’ understandings about what genetic susceptibility tests can achieve, what they cannot achieve, and the risks they pose should be more realistic after testing than beforehand. However, no study has previously compared pre- and post-test perceptions about the pros and cons of genetic susceptibility testing.
This report explores pre- and post-test perceptions of the pros and cons of genetic susceptibility testing in the context of apolipoprotein E (APOE) testing conducted as part of a genetic risk assessment for Alzheimer disease (AD). The APOE gene has three major alleles: ε2, ε3, and ε4. The APOE ε4 allele is among the best predictors of AD risk,28 and 20% or more of most ethnic groups are carriers of an ε4 allele.29 APOE is considered a susceptibility test because it has limited predictive value: ε4 carriers may live long lives without ever developing the disease and noncarriers still have risk for AD. Although proven prevention strategies are lacking, our previous studies have found that many individuals still perceive genetic susceptibility testing for AD to have substantial utility, from being able to reduce anxiety about AD risk to informing decisions about long-term care (LTC) insurance.10,30 However, these analyses did not explicitly compare pre- and post-test perceptions.
The analysis that follows compares pre- and post-test perceptions about the pros and cons of APOE genetic susceptibility testing for AD in the Risk Evaluation and Education for AL-zheimer Disease (REVEAL) Study.31 On the basis of the research on BRCA1/2 genetic testing decisions showing high post-test satisfaction with decisions,25,26 we hypothesized that participants who completed APOE genetic susceptibility testing for AD would rate its pros higher than its cons. On the basis of the aforementioned possible misconceptions about genetics and genetic services, we also hypothesized that ratings of pros and cons would change after testing. Finally, we tested whether the kind of pretest education that participants received or the results of the genetic risk assessments had any impact on how pretest ratings of the perceived pros and cons changed 12 months after disclosure.
Overview
Data were analyzed from the second trial of the REVEAL Study, a series of multicenter randomized clinical trials examining the psychosocial and behavioral impact of providing AD susceptibility testing with APOE genotype disclosure.31 In this trial, conducted between 2003 and 2006, participants were randomized into two arms in which they received either a “conventional” or an abbreviated “condensed” pretest educational protocol. The study took place at four academic centers: Boston University School of Medicine in Boston, MA, Case Western Reserve Medical School in Cleveland, OH, Weill School of Medicine in New York, NY, and Howard University School of Medicine in Washington, DC. Preliminary results of the randomized trial have been presented elsewhere3234 and are being reported separately. This article reports a secondary analysis comparing pre- and post-test perceptions of pros and cons.
Participants and procedures
Participants were adult first-degree relatives (i.e., parents, siblings, or children) of patients with AD, for whom the average age of onset of AD within the family was 60 years or more. Participants completed a baseline assessment that included a telephone interview and self-administered mailed questionnaires and were then randomized to one of two pretest educational protocols. The conventional education arm had in-person educational sessions with a genetic counselor followed by genetic counselor-directed discussions. The condensed education arm substituted educational brochures for the in-person educational sessions and simply provided an opportunity for participants to ask questions. Participants in both arms of the study were provided with their genotype and numerical risk assessments and risk curves based on their APOE genotype, age, gender, self-identified ethnicity, and family history.35,36 Scripted messages and printed materials in both arms addressed the same topics, including pros and cons, as shown in Table 1. Informed consent documents signed at enrollment and again just before the blood draw for genotyping reiterated the same points.
Table 1
Table 1
Pros and cons of AD genetic risk assessment as described in educational materials and informed consent forms
After blood draw and genotyping, participants in both arms received personalized AD risk estimates through age 85 years ranging from 13% to 77% depending on gender, self-identified ethnicity, family history of AD, and APOE genotype. Participants also received remaining AD risk estimates that incorporated their current ages. Participants were then followed up for a year after disclosure.
Protocols were approved by an External Advisory Board and institutional review boards at each study site.
Measures
Demographics
Gender, ethnicity, age, education, employment status, and income data were collected via self-report during the initial phone interview.
Educational protocol
Subjects were coded as receiving the conventional or condensed educational protocols based on randomization status.
APOE genotype
APOE genotype was dichotomized depending on whether a participant carried at least one copy of the APOE ε4 allele associated with increased risk for AD or not.
Pros and cons
Perceived pros and cons of genetic susceptibility testing for AD were assessed in the baseline written questionnaire administered before pretest education and again in the 12-month follow-up questionnaire. Scales measuring perceived pros and cons of genetic testing for AD were modified from research on genetic testing for hereditary breast and ovarian cancer4,37 and implemented in subsequent studies of attitudes about AD susceptibility testing, including prior REVEAL Study trials.3,10 Questionnaires included a section that offered reasons “why someone might take a genetic test for AD” (Pros) and a separate section that offered reasons “why someone might not want to take a genetic test for AD” (Cons). See Table 3 for a list of the specific items. Participants rated how important each reason was to them on a Likert scale of 1 (not at all) to 5 (extremely). Overall Pros (range: 1–5) was calculated by taking the mean of the ratings of the 11 pros items, with higher scores indicating more favorable perceptions about testing. Overall Cons (range: 1–5) was similarly calculated taking the mean of the ratings of the 10 cons items, with higher scores indicating more reservations about testing. Confirmatory factor analysis showed strong internal consistency for both scales: Cronbach’s alpha was 0.81 at baseline and 0.87 at 12 months for the pros scale and 0.81 for the cons scale at both baseline and 12 months.
Table 3
Table 3
Ratings of individual pros and individual cons at baseline and at 12 months ordered by magnitude of change (1 = not at all important, 5 = extremely important)
Exploratory factor analysis suggested that three items from the cons scale, namely “the results could affect my employment,” “the results could affect my health insurance,” and “the results could change how people look or act toward me,” comprised a Discrimination Fears subscale. In addition to face validity, the subscale demonstrated acceptable internal consistency, with Cronbach’s alpha scoring 0.70 at baseline and 0.79 at 12 months. We therefore conducted additional analyses on the mean ratings of items in this subscale (range: 1–5).
Nonresponse on items specific to children (up to 20 instances on each item) was scored “not at all important” if the subject reported having no children. Nonresponse on the item, “the results could affect my employment” (13 instances) was also scored “not at all important” if the subject reported being retired. Nonresponses on all other items (up to six instances per item) were imputed using the median scores across subjects on the items.
Data analysis
Only participants who completed the 12-month follow-up were analyzed. Chi-square analyses, Pearson product-moment correlations, and Spearman rank correlations were used to test whether demographic or study-related factors were associated with study dropout between the baseline assessment and the 12-month follow-up. Paired t-tests were used to compare overall pros against overall cons. Paired t-tests were also used to examine how overall pros, overall cons, and discrimination fears changed between baseline and follow-up, and independent samples t-tests were used to examine whether educational protocols or APOE genotype were associated with such changes. Finally, paired t-tests were used to assess whether individual reasons for and against testing changed between baseline and follow-up, and independent samples t-tests were used to determine whether changes from baseline differed according to educational protocol or APOE genotype. One-sided tests were used to test the hypothesis that overall pros would be rated higher than overall cons. All other tests were two-sided.
Demographics and study retention
Three hundred and twenty-nine participants completed the baseline survey, and 299 of them (91%) received AD risk estimates with APOE genotype disclosure. Ultimately, 293 participants (89%) retained through the 12-month follow-up and were included in data analyses. Demographics of these participants are presented in Table 2. A majority of participants referred themselves to the study, learning about the study through presentations given by investigators from the REVEAL Study, other research studies, postings on the internet, community newsletters, health fairs, or via the Alzheimer’s Association.
Table 2
Table 2
Participant demographics (n = 273) at the 12-month follow-up
Three demographic factors were found to be associated with study dropout between the baseline assessment and the 12-month follow-up: no current employment (χ2 = 8.64, P = 0.003), lower household income (ρ = 0.21, P < 0.001), and less education (r = 0.18, P = 0.001). Higher ratings of overall pros at baseline were associated with study dropout before the 12-month follow-up (r = 0.11, P = 0.049) but not before results disclosure (r = 0.01, P = 0.920). Higher ratings of overall cons at baseline were associated with study dropout by disclosure (r = 0.17, P = 0.003) and the 12-month follow-up (r = 0.16, P = 0.004). Discrimination fears were not associated with study dropout by 12 months (r = 0.08, P = 0.172)
Overall pros, overall cons, and discrimination fears
Participants rated the items on the pros scale much higher than items on the cons scale both before and after testing as hypothesized. At baseline, the mean overall pros score was 3.53, whereas the mean overall cons score was 1.83 (t = 33.4, P < 0.001). At 12 months, the mean overall pros score was 3.33, whereas the mean overall cons score was 1.88 (t = 26.2, P < 0.001). Changes from baseline were also noted. On average, overall pros were rated slightly lower 12 months after disclosure than at baseline (3.33 vs. 3.53, t = 4.82, P < 0.001). Overall cons were rated approximately the same at both time points (1.88 vs. 1.83, t = 1.29, P = 0.199) but scores on the discrimination fears scale were higher at 12 months than baseline (2.07 vs. 1.92, t = 2.54, P = 0.012). Changes on all scales were not associated with the educational protocol participants received (pros: Δ = −0.01, t = −0.07, P = 0.944; cons: Δ = 0.02, t = 0.29, P = 0.769; and discrimination fears: Δ = 0.01, t = 0.06, P = 0.954) or APOE genotype (overall pros: Δ = −0.06, t = −0.67, P = 0.502; overall cons: Δ = 0.02, t = 0.22, P = 0.830; and discrimination fears: Δ = 0.08, t = 0.65, P = 0.517).
Changes to individual pros and cons
Table 3 summarizes how ratings of individual pros and cons changed at follow-up. Six pros were rated lower at 12 months compared with baseline. The greatest change occurred on the item “to seek information on preventive measures,” where 43% of participants rated the benefit lower at follow-up than at baseline. Changes on that item were associated with APOE genotype, where ε4 carriers lowered their ratings less at follow-up than noncarriers (Δ = 0.28, t = 2.00, P = 0.047). “To give information about my children’s possible risk of AD” was also rated lower at follow-up, but ε4 carriers lowered their ratings more at follow-up than noncarriers (Δ = −0.47, t = 2.97, P = 0.003). Other individual items rated lower at follow-up than baseline, regardless of genotype, were “the need to make arrangements for my long-term care,” “to know more about my risk in case better treatments become available,” “the desire to contribute to research on AD,” and “the desire to start doing things sooner than I had planned to.” Changes in ratings of individual pros items were not associated with APOE genotype or educational protocol except for the two items noted above.
The ratings of four con items also showed changes. Three that were rated higher at follow-up than baseline were “the test does not give me a definite answer about whether or not I might get AD,” “there is no way to cure or prevent AD,” and “the results could affect my employment.” In contrast, “the test procedure would be too burdensome” was rated lower at follow-up than at baseline. No changes were associated with APOE genotype or educational protocol.
This is the first analysis to explore how perceptions about the pros and cons about genetic susceptibility tests change after actual testing. Our data supported the hypothesis that people who seek and obtain APOE genetic testing as part of obtaining AD risk assessment retain strong positive attitudes about the experience but generally reduce their endorsements of the pros and increase their concerns about risk of discrimination after undergoing testing. Among the topics where perceptions of the pros were diminished after disclosure, this drop was particularly striking in the items “to seek information about preventative measures” and “to know about risk in case better treatments become available.” Similarly, there was an increase in the perceived con item “lack of a cure or prevention.” One of the main reasons APOE testing of asymptomatic patients for AD risk is not part of standard clinical practice is the absence of options to prevent or delay disease onset,3840 and educational materials in the REVEAL Study emphasized that “there are no proven ways to prevent Alzheimer disease.” Despite this clear disclaimer, it is possible that some participants sought susceptibility testing thinking that genetic susceptibility testing would expose them to new strategies for reducing or delaying AD risk, especially when conducted as part of research. Anecdotally, many participants asked REVEAL Study personnel whether the investigative team was also associated with prevention and treatment trials, although such queries were not formally tracked.
At the same time, APOE ε4 carriers did not lower their rating of “to seek information on preventative measures” as much as noncarriers did, suggesting that they found greater utility to the genetic risk assessment in terms of thinking about prevention measures. This finding is consistent with prior analyses of REVEAL Study data showing ε4 carriers to be more likely to report health behavior changes than noncarriers, particularly in their consumption of dietary supplements and vitamins.41,42 It seems that those who learn they are ε4 carriers may feel justified in using unproven preventative measures. If so, clinicians who provide predictive genetic testing should be sure that efficacy expectations about such measures are realistic and that test recipients do not pursue strategies—such as off-label use of pharmaceuticals—that may be detrimental to their health.
Another theme that emerged in the data related to the risk of future disability. “To make arrangements for long-term care” and “to start doing things sooner” were reasons for testing that were, on average, rated lower after testing than before. This finding was surprising given prior REVEAL Study data showing that APOE genetic susceptibility test results can inform the purchase of LTC insurance.30,43 It is possible that participants who hoped to use testing to inform decisions about the future, such as LTC insurance purchasing, were dissuaded because of greater sensitivity to the limited positive and negative predictive value of APOE for AD. Supporting this argument, participants rated the lack of a definitive answer about future AD onset as a stronger con at follow-up.
Participants also tended to rate the reason “to give information about my children’s possible risk for AD” lower at follow-up than at baseline. The change varied by APOE status, with ε4 carriers lowering their ratings more than noncarriers. This difference may be attributable to concern or guilt about passing increased risk for AD risk along to children, supported by evidence that carriers feel more test-specific distress in the short-term than noncarriers.31 Another possibility is that carriers may consider sharing “bad” news to be more stressful than sharing “good” news.
A final benefit that was rated lower after testing was “the desire to contribute to research on AD.” This finding is interesting given prior findings that endorsement of this reason predicted follow-through on intentions to seek testing in prior analyses.10 It is possible that the burdens of study participation—which included regular follow-ups and completion of questionnaires over a 1-year period after disclosure—tempered the altruism many participants felt when they originally enrolled in the study, and anecdotal evidence suggested that some participants thought the surveys and time required for the study were excessive. On the other hand, participants tended to rate testing burdens lower at follow-up than at baseline. It may simply be that testing was interesting while study follow-up was less so.
The increases in concern about discrimination merit attention considering federal legislation enacted after data collection ended in 2006. The Genetic Information Nondiscrimination Act of 2008 has been hailed as a success for genomic medicine because it provides federal protections against employment and health insurance discrimination based on genetic information, including genetic test results.44 Although many such protections had already been provided in a patchwork of state legislations—including all states and districts hosting REVEAL Study sites at the time of the study—the passage of Genetic Information Nondiscrimination Act has likely raised awareness about the existence of legal protections, especially considering the media attention its passage has generated after 13 years of debate. Discrimination fears related to genetic testing may not be so strong in the future.
Several limitations should be kept in mind while interpreting results. Our methodology does not allow us to make determinations about what reasons may have caused the changes in perceptions of pros and cons. After participants completed the baseline assessment, participants received educational preparation for the study, underwent a second informed consent step, and had in-person discussions with a clinician. In each of those steps, participants received information about the benefits, risks, and limitations of AD genetic susceptibility testing, and any or all of these activities could have contributed to changes in perceptions of pros and cons. Furthermore, participants lacking data at 12 months were omitted from analysis, possibly biasing results. Among this group were those with lower presumed socioeconomic status (those with the less education, lower household incomes, or were not currently employed) in addition to those who perceived greater pros and greater cons at baseline. In addition, our close-ended survey items are unlikely to have captured all pros and cons relevant to a given participant. Finally, significance levels were not adjusted to account for the number of comparisons conducted because the study was not powered for this secondary analysis, thus increasing the risk for false-positive findings.
Nevertheless, the findings from this analysis have important implications for the way genetic services are delivered. Our analyses show strong positive attitudes toward genetic susceptibility testing for AD, even after a genetic risk assessment that includes APOE genotyping. Additional genetic tests associated with risk for AD and tests for other untreatable diseases are likely to become available in the future.24 If so, we can expect those who have already undergone AD susceptibility testing to have favorable attitudes toward the new ones.
Finally, if post-test ratings represent a more accurate appraisal of the benefits, risks, and limitations of APOE genetic testing for AD risk, then the minor changes observed in our analysis demonstrate slight discordance between how participants anticipated they would use genetic risk information and how they actually used it. Experts tend to agree that the best decisions are made when expectations are brought into alignment with true outcomes through a process of education and deliberation.45 The condensed educational protocol tested in the second REVEAL Study trial imposed substantially less burdens on both clinicians and test recipients (i.e., one fewer study visit and a reduction in clinic time of over 40 minutes). The lack of differences in perceptions of cons and pros by educational protocol in our study suggests that condensed protocols can have the same effect as more time-consuming ones, at least on altering the perceptions individuals have about what APOE testing can achieve. As genetic testing for susceptibility becomes more common, providers will need to seek the right balance between feasibility and effectiveness in pretest education to ensure that people seeking such testing are making informed decisions.
Acknowledgments
This study was funded by the following NIH grants: HG02213, HG005092, AG027841, AG09029, AG13846, RR00533, and RR10284.
The authors thank Erin Linnenbringer, Sarah Tersegno, and Lindsay Zausmer at the University of Michigan School of Public Health for their assistance with manuscript preparation.
Footnotes
Disclosure: The authors declare no conflict of interest.
1. Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med. 2009;11:265–278. [PubMed]
2. Roberts JS, Connell CM, Cisewski D, Hipps YG, Demissie S, Green RC. Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17:19–26. [PubMed]
3. Roberts JS. Anticipating response to predictive genetic testing for Alzheimer’s disease: a survey of first-degree relatives. Gerontologist. 2000;40:43–52. [PubMed]
4. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA. 1996;275:1885–1892. [PubMed]
5. Rosenstock IM. Historical origins of the Health Belief Model. Health Educ Monogr. 1974;2:328–335.
6. Ajzen I. Attitudes, personality, and behavior. Homewood: Dorsey Press; 1988.
7. Hughes C, Gomez-Caminero A, Benkendorf J, et al. Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Couns. 1997;32:51–62. [PubMed]
8. Hipps YG, Roberts JS, Farrer LA, Green RC. Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer’s disease. Genet Test. 2003;7:39–44. [PubMed]
9. Donovan KA, Tucker DC. Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. J Behav Med. 2000;23:15–36. [PubMed]
10. Roberts JS, LaRusse SA, Katzen H, et al. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17:86–93. [PubMed]
11. Kessler L, Collier A, Brewster K, et al. Attitudes about genetic testing and genetic testing intentions in African American women at increased risk for hereditary breast cancer. Genet Med. 2005;7:230–238. [PubMed]
12. Thompson HS, Valdimarsdottir HB, Jandorf L, Redd W. Perceived disadvantages and concerns about abuses of genetic testing for cancer risk: differences across African American, Latina and Caucasian women. Patient Educ Couns. 2003;51:217–227. [PubMed]
13. Genetics and Public Policy Center. Chapter 2: Public awareness and knowledge. In: Kalfoglou A, Suthers K, Scott J, Hudson K, editors. Reproductive genetic testing: what America thinks. Washington, DC: Genetics and Public Policy Center; 2004. pp. 7–10.
14. National Science Board. Science and engineering indicators 2008. 7-1. Vol. 1. Arlington: National Science Foundation; 2008. Science and technology: public attitudes and understanding; pp. 7–47.
15. Lanie AD, Jayaratne TE, Sheldon JP, et al. Exploring the public understanding of basic genetic concepts. J Genet Couns. 2004;13:305–320. [PubMed]
16. Christensen KD, Jayaratne TE, Roberts JS, Kardia SLR, Petty EM. Understandings of basic genetics in the United States: results from a national survey of black and white men and women. Public Health Genomics. 2010;13:467–476. [PMC free article] [PubMed]
17. Singer E, Antonucci T, Van Hoewyk J. Racial and ethnic variations in knowledge and attitudes about genetic testing. Genet Test. 2004;8:31–43. [PubMed]
18. Nelkin D, Lindee MS. The DNA mystique: the gene as a cultural icon. Ann Arbor: University of Michigan; 2004.
19. Bubela TM, Caulfield TA. Do the print media “hype” genetic research? A comparison of newspaper stories and peer-reviewed research papers. CMAJ. 2004;170:1399–1407. [PMC free article] [PubMed]
20. Holtzman NA, Bernhardt BA, Mountcastle-Shah E, Rodgers JE, Tambor E, Geller G. The quality of media reports on discoveries related to human genetic diseases. Community Genet. 2005;8:133–144. [PubMed]
21. Matloff E, Caplan A. Direct to confusion: lessons learned from marketing BRCA testing. Am J Bioeth. 2008;8:5–8. [PubMed]
22. Gray S, Olopade OI. Direct-to-consumer marketing of genetic tests for cancer: buyer beware. J Clin Oncol. 2003;21:3191–3193. [PubMed]
23. Meiser B, Dunn S. Psychological effect of genetic testing for Huntington’s disease: an update of the literature. West J Med. 2001;174:336–340. [PMC free article] [PubMed]
24. Roberts JS, Barber M, Brown TM, et al. Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial. Genet Med. 2004;6:197–203. [PubMed]
25. Bluman LG, Rimer BK, Sterba KR, et al. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses. Psychooncology. 2003;12:410–427. [PubMed]
26. Klemp JR, O’Dea A, Chamberlain C, Fabian CJ. Patient satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial. Fam Cancer. 2005;4:279–284. [PubMed]
27. Bloss CS, Ornowski L, Silver E, et al. Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet Med. 2010;12:556–566. [PubMed]
28. Morris JC. Dementia update 2005. Alzheimer Dis Assoc Disord. 2005;19:100–117. [PubMed]
29. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? Ann Hum Genet. 1999;63:301–310. [PubMed]
30. Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC. Genetic testing for Alzheimer’s disease and its impact on insurance purchasing behavior. Health Aff. 2005;24:483–490. [PMC free article] [PubMed]
31. Green RC, Roberts JS, Cupples LA, et al. A randomized trial of APOE genotype disclosure for risk of Alzheimer’s disease: the REVEAL Study. N Engl J Med. 2009;361:245–254. [PMC free article] [PubMed]
32. Green RC, Roberts JS, Linnenbringer E, et al. Impact of a condensed protocol for disclosing genetic susceptibility for Alzheimer’s disease: the REVEAL Study. Neurology. 2006;66:A349–A350.
33. Roberts S, Linnenbringer E, Butson MB, et al. Impact of a condensed protocol for disclosing APOE genotype to first-degree relatives of people with Alzheimer’s disease. Alzheimers Dement. 2008;4(4, suppl 1):T454–T455.
34. Green RC, Roberts JS, Chen C, et al. Comparing the impact of a condensed vs extended protocol for disclosure of APOE to relatives of patients with AD: the REVEAL Study. Alzheimers Dement. 2007;3(3, suppl 1):S184.
35. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: the REVEAL Study. Genet Med. 2004;6:192–196. [PubMed]
36. Christensen KD, Roberts JS, Royal CDM, et al. Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL Study experience. Genet Med. 2008;10:207–214. [PMC free article] [PubMed]
37. Lerman C, Seay J, Balshem A, Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet. 1995;57:385–392. [PubMed]
38. Consensus statement on predictive testing for Alzheimer disease. Alzheimer Dis Assoc Disord. 1995;9:182–187. [PubMed]
39. Apolipoprotein E genotyping in Alzheimer’s disease. National Institute on Aging/Alzheimer’s Association Working Group. Lancet. 1996;347:1091–1095. [PubMed]
40. American College of Medical Genetics (ACMG)/American Society of Hum Genet (ASHG) Working Group on ApoE and Alzheimer disease. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA. 1995;274:1627–1629. [PubMed]
41. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord. 2008;22:94–97. [PMC free article] [PubMed]
42. Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr. 2010;91:1402–1407. [PubMed]
43. Taylor DH, Jr, Cook-Deegan RM, Hiraki S, Roberts JS, Blazer DG, Green RC. Genetic testing for Alzheimer’s and long-term care insurance. Health Aff. 2010;29:102–108. [PMC free article] [PubMed]
44. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times—the Genetic Information Nondiscrimination Act of 2008. N Engl J Med. 2008;358:2661–2663. [PubMed]
45. Elwyn G, Miron-Shatz T. Deliberation before determination: the definition and evaluation of good decision making. Health Expect. 2010;13:139–147. [PubMed]